Subjective and polysomnographic effects of milnacipran on sleep in depressed patients

Lemoine, P.; Faivre, Thierry

doi:10.1002/hup.600

Cited by 22 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, in another study, milnacipran administration in depressed subjects improved sleep only when depression was also improved, further supporting the finding that milnacipran does not affect sleep continuity directly. 30 The lack of agreement between sleep diaries and PSG is consistent with reports from the literature that good sleepers show concordance between PSG and sleep diaries while poor sleepers do not.…”

Section: Discussionsupporting

confidence: 89%

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study

Ahmed

Aamir

Jishi

et al. 2016

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

Objective: This study examined the effects of milnacipran on polysomnographic (PSG) measures of sleep and subjective complaints in patients with fibromyalgia and disturbed sleep. Methods: This was a single-site, double-blind, placebo-controlled, two-period crossover PSG study. Eligible subjects (aged 28-72 y) were randomized (1:1) to milnacipran (100 mg/d) or placebo for crossover period 1, and vice versa for period 2. Each crossover period comprised a dose-escalation and dose-maintenance phase, with a 2-w taper/washout between periods. In-laboratory PSGs were collected at baseline, and at the end of each treatment period. The primary endpoints were the difference in PSG-recorded wake after sleep onset (WASO), number of awakenings after sleep onset (NAASO), and sleep efficiency (SE) between 4 w of maintenance treatment with milnacipran and placebo. Other PSG measures, subject-rated sleep, fatigue, physical functioning, and pain were assessed. Post hoc analysis was performed in subjects showing at least 25% reduction in pain from baseline in the Brief Pain Inventory Score (responders). Results: Of 19 subjects randomized, 15 completed both periods. Subjects treated with milnacipran showed no significant improvements in WASO and NAASO, but showed reduced SE (p = 0.049). Milnacipran did not show significant improvement in other PSG parameters or subjective endpoints. Two thirds of completers met responder criteria and additionally showed a significant improvement in daily effect of pain (p = 0.043) and subjective sleep quality (p = 0.040). Conclusion:The data suggest that milnacipran is not sedating in most patients with fibromyalgia and improvements in sleep are likely a result of pain improvement. Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT01234675 Keywords: fibromyalgia, milnacipran, polysomnography, pain, sleep quality Citation: Ahmed M, Aamir R, Jishi Z, Scharf MB. The effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebocontrolled, two-way crossover study.

show abstract

Section: Discussionsupporting

confidence: 89%

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study

Ahmed

Aamir

Jishi

et al. 2016

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

show abstract

“…Treatment with another SNRI, milnacipran, did not show significant changes on sleep PSG parameters. No effect was observed on REM sleep, and only one study found increased ROL [ 86 ]. The study of Rahmani et al [ 87 ] reported increased total awake time and decreased NREM sleep after 7 days of milnacipran treatment of depressive patients.…”

Section: The Effects Of Antidepressants On Sleepmentioning

confidence: 99%

Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment

Hutka

Krivosova

Muchova

et al. 2021

IJMS

View full text Add to dashboard Cite

Sleep problems are frequently associated with the principal diagnostic criteria for many mental disorders. Alterations in the sleep of depressive patients are of high clinical significance because continuous sleep problems raise the chance of relapse, recurrence, or suicide, as well as the need for augmenting medications. Most antidepressants have been proven to influence the sleep architecture. While some classes of antidepressants improve sleep, others may cause sleep impairment. The successful treatment of depressive disorder also requires an understanding of the effects of antidepressants on sleep. This article briefly reviews the physiology of sleep and the typical alterations in the sleep architecture in depressive patients and updates the different effects of the majority of antidepressants including novel drugs in clinical practice on sleep. The summary of the updated scientific findings of the relationship between depression and sleep disturbances could be clinically beneficial in choosing the best medication for depressive patients with concurrent sleep disorders.

show abstract

“…Duloxetine demonstrates effectiveness in reducing PTSD nightmares ( 70 ) and has a similar effect on sleep as venlafaxine ( 71 ): reduced length of REM sleep, fragmented sleep, and increase in periodic limb movement. For milnacipran , no increase in dream recall was observed ( 72 ).…”

Section: Effects Of Antidepressants On Dream Recallmentioning

confidence: 99%

Dreams, Sleep, and Psychotropic Drugs

Nicolas

Ruby

2020

Front. Neurol.

View full text Add to dashboard Cite

Over the past 60 years, the impact of psychotropic drugs on dream recall and content has been scarcely explored. A review of the few existing experimental results on the topic leads us to the following conclusions. For antidepressant drugs, in the great majority, they reduce dream recall frequency (DRF), and the improvement of depressive symptoms is associated with an increase of positive emotion in dream content. For sedative psychotropic drugs, their improvement of sleep quality is associated with a reduction of DRF, but the effect on dream content is less clear. Few occurrences of nightmare frequency increase have been reported, with intake of molecules disturbing sleep or with the withdrawal of some psychotropic drugs. Importantly, the impact of psychotropic drugs on rapid eye movement (REM) sleep does not explain DRF modulations. The reduction of intra-sleep awakenings seems to be the parameter explaining best the modulation of DRF by psychotropic drugs. Indeed, molecules that improve sleep continuity by reducing intra-sleep awakenings also reduce the frequency of dream recall, which is coherent with the "arousal-retrieval model" stating that nighttime awakenings enable dreams to be encoded into long-term memory and therefore facilitate dream recall. DRF is nonetheless influenced by several other factors (e.g., interest in dreams, the method of awakening, and personality traits), which may explain a large part of the variability of results observed and cited in this article.

show abstract

Subjective and polysomnographic effects of milnacipran on sleep in depressed patients

Cited by 22 publications

References 18 publications

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study

Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment

Dreams, Sleep, and Psychotropic Drugs

Contact Info

Product

Resources

About